Galera Therapeutics, Inc.

0.14 USD
+0.06 (+68.64%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Galera Therapeutics, Inc. stock is down -20.83% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 4 June’s closed higher than May.

About Galera Therapeutics, Inc.

Galera Therapeutics, Inc. focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the. treatment of. radiotherapy induced severe oral mucositis in patients with head and neck cancer.